Norgestrel and Ethinyl Estradiol Tablets USP (RLD: Lo/Ovral-28) had estimated annual sales of US $33 million in the US
Accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
Establishes connected software and data foundation for the future with next-generation life sciences CRM and harmonized customer data
The newly established business will be looking for high-quality, mid- to late-stage assets, clinically focused on the United States market
Phase 3 data expected in the second half of 2024
The company has raised US$4.5 million in funding for its AI operating system
Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients
Total transaction value of the divestment is Rs. 3,660 million
This product will be manufactured at Lupin’s Pithampur facility in India
Subscribe To Our Newsletter & Stay Updated
